News & Views

News and updates from our areas of work

UNITAID releases demand forecast for malaria medicines

25 avr 2016 | Under News | Posted by

UNITAID, the international funding agency focused on market information, fast-tracking access and reducing costs of new more effective medicines, technologies and systems for HIV/AIDS, TB and malaria, as just released to two reports on the demand for antimalarial medicines: artemisinin combination therapies (ACTs), artemisinin monotherapies and rapid diagnostic tests for malaria.

The Global Forecast report has been produced by a consortium including the Clinton Health Access Initiative (CHAI), IMS Health (IMS), and the University of California, San Francisco (UCSF). TESS Development Advisors contributes to this report as a sub-contractor specialised in the field of malaria treatment and analysis of product demand.

These reports project « rising demand for malaria diagnostics and treatment through 2018, despite recent sharp declines in malaria prevalence worldwide. Over 400 million treatments and a vast scale-up in the market for malaria rapid diagnostic tests are needed over the next three years to meet global targets for eliminating malaria.

The report estimates that global demand for all antimalarial medicines will grow from 1.3 billion treatments in 2015 to approximately 1.4 billion treatments by 2018. This is substantially larger than the estimated 214 million malaria cases in 2014 owing to limited use of pre-treatment diagnosis and excessive presumptive treatment with antimalarials, especially in the private sector. Global procurement of quality-assured ACTs is projected to grow from 378 million treatments in 2015 to 457 million treatments in 2016. This is largely due to an increase in donor funded purchases in the public sector for countries where malaria is endemic. Non-quality assured ACTs comprise about a quarter of estimated global ACT demand, which is mostly driven by the private sector. This is a cause for concern as use of potentially sub-standard drugs could increase the risk of patients dying. Besides, it can also lead to the emergence of artemisinin-resistant malaria in Africa. »

The full demand forecast report is available here.